Matthieu Besutti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Matthieu Besutti has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Fiona Ecarnot
SINERGIES, University of Franche-Comté, Besançon, France
5 shared publications Nicolas Meneveau
Department of Cardiology, University Hospital Besançon, Besançon, France; SINERGIES, Université Marie & Louis Pasteur, 25000 Besançon, France; F-CRIN, INNOVTE network, France
5 shared publications- François Schiele
Department of Cardiology, University Hospital Besançon, Besançon, France
4 shared publications Romain Chopard
Department of Cardiology, University Hospital Besançon, Besançon, France; SINERGIES, Université Marie & Louis Pasteur, 25000 Besançon, France; F-CRIN, INNOVTE network, France
4 shared publications- Romain Chopard
Department of Cardiology, University Hospital Besançon, Besançon, France
4 shared publications - Nicolas Meneveau
Department of Cardiology, University Hospital Besançon, Soins intégrés, nanomédecine, IA et ingénierie pour la santé, University of Franche-Comté, French Clinical Research Infrastructure Network, Investigation Network On Venous Thromboembolism, France (N. Meneveau, M.B.).
3 shared publications
Latest Publications
- Open Access
- 12 May 2026
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
Carotid Bypass: Insights from a Real World Multicentre French Cohort
- 12 May 2026
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
Open AccessCarotid Bypass: Insights from a Real World Multicentre French Cohort
- Open Access
- 15 January 2026
- Published by Elsevier in Archives of Cardiovascular Diseases
- Vol. 119 (1) , 15-24
The STRAT clinical risk score to predict early ischaemic stroke post-TAVI: The FRANCE-TAVI registry
- 15 January 2026
- Published by Elsevier in Archives of Cardiovascular Diseases
- Vol. 119 (1) , 15-24
Open AccessThe STRAT clinical risk score to predict early ischaemic stroke post-TAVI: The FRANCE-TAVI registry
- Open Access
- 23 October 2025
- Published by Elsevier in International Journal of Cardiology
- Vol. 444, 133979
Diagnostic yield of referring patients for invasive coronary angiography primarily based on high CAC scores: Positive predictive value for obstructive coronary artery disease in a consecutive real-life cohort
- 23 October 2025
- Published by Elsevier in International Journal of Cardiology
- Vol. 444, 133979
Open AccessDiagnostic yield of referring patients for invasive coronary angiography primarily based on high CAC scores: Positive predictive value for obstructive coronary artery disease in a consecutive real-life cohort
- Open Access
- 13 September 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (32) , 105350
Dual Percutaneous Repair for Aortic Annulus Rupture After Balloon-Expandable TAVR
- 13 September 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (32) , 105350
Open AccessDual Percutaneous Repair for Aortic Annulus Rupture After Balloon-Expandable TAVR
- Open Access
The STRAT Clinical Risk Score to Predict Early Ischemic Stroke Post-TAVI: findings from the FRANCE-TAVI registry
Background: Practitioners recommending transcatheter aortic valve implantation (TAVI) currently lack reliable tools to predict periprocedural ischemic stroke risk. We aimed to develop and internally validate a clinical risk score to accurately stratify this risk. Methods: Using data from the nationwide, multicenter FRANCE-TAVI registry, we developed a clinical predictive risk score for 30-day ischemic stroke post-TAVI using multivariable logistic regression analysis. The model was internally validated through cross-validation techniques. Results: Among 62,747 patients, 1,712 (2.7%), experienced ischemic stroke within 30 days. Nine clinical predictors were identified, namely female sex, age >85 years, weight 1) episodes of acute heart failure, severe mobility reduction, diabetes, and creatinine clearance <60 mL/min. The resulting scoring model demonstrated good accuracy (Brier score, 0.17), moderate discrimination (C-index, 0.63), and excellent calibration as assessed by calibration plots, calibration-in-the-large, and calibration slope. The score categorized patients into low (90.2% of the population), intermediate (8.0%) and high-risk (1.8%) groups. Observed stroke rates increased progressively across these groups, from 2.25% in the low-risk group to 6.51% in the intermediate-risk group and 10.10% in the high-risk group. Conclusions: This newly developed STRAT score is a clinical, practical, and effective tool for predicting early ischemic stroke in patients undergoing TAVI. It may help tailor preventive strategies. Further studies are necessary to externally validate this score and evaluate its impact on clinical decision-making.
Open AccessThe STRAT Clinical Risk Score to Predict Early Ischemic Stroke Post-TAVI: findings from the FRANCE-TAVI registry
Background: Practitioners recommending transcatheter aortic valve implantation (TAVI) currently lack reliable tools to predict periprocedural ischemic stroke risk. We aimed to develop and internally validate a clinical risk score to accurately stratify this risk. Methods: Using data from the nationwide, multicenter FRANCE-TAVI registry, we developed a clinical predictive risk score for 30-day ischemic stroke post-TAVI using multivariable logistic regression analysis. The model was internally validated through cross-validation techniques. Results: Among 62,747 patients, 1,712 (2.7%), experienced ischemic stroke within 30 days. Nine clinical predictors were identified, namely female sex, age >85 years, weight 1) episodes of acute heart failure, severe mobility reduction, diabetes, and creatinine clearance <60 mL/min. The resulting scoring model demonstrated good accuracy (Brier score, 0.17), moderate discrimination (C-index, 0.63), and excellent calibration as assessed by calibration plots, calibration-in-the-large, and calibration slope. The score categorized patients into low (90.2% of the population), intermediate (8.0%) and high-risk (1.8%) groups. Observed stroke rates increased progressively across these groups, from 2.25% in the low-risk group to 6.51% in the intermediate-risk group and 10.10% in the high-risk group. Conclusions: This newly developed STRAT score is a clinical, practical, and effective tool for predicting early ischemic stroke in patients undergoing TAVI. It may help tailor preventive strategies. Further studies are necessary to externally validate this score and evaluate its impact on clinical decision-making.
- Open Access
Incidence of atrial fibrillation in cryptogenic stroke with patent foramen ovale closure: protocol for the prospective, observational PFO-AF study
Introduction After closure of patent foramen ovale (PFO) due to stroke, atrial fibrillation (AF) occurs in up to one in five patients. However, data are sparse regarding the possible pre-existence of AF in these patients prior to PFO closure, and about recurrence of AF in the long term after the procedure. No prospective study to date has investigated these topics in patients with implanted cardiac monitor (ICM). The PFO-AF study (registered with ClinicalTrials.gov under the number NCT04926142) will investigate the incidence of AF occurring within 2 months after percutaneous closure of PFO in patients with prior stroke. AF will be identified using systematic ICM. Secondary objectives are to assess incidence and burden of AF in the 2 months prior to, and up to 2 years after PFO closure. Methods and analysis Prospective, multicentre, observational study including 250 patients with an indication for PFO closure after stroke, as decided by interdisciplinary meetings with cardiologists and neurologists. Patients will undergo implantation of a Reveal Linq device (Medtronic). Percutaneous PFO closure will be performed 2 months after device implantation. Follow-up will include consultation, ECG and reading of ICM data at 2, 12 and 24 months after PFO closure. The primary endpoint is occurrence of AF at 2 months, defined as an episode of AF or atrial tachycardia/flutter lasting at least 30 s, and recorded by the ICM and/or any AF or atrial tachycardia/flutter documented on ECG during the first 2 months of follow-up. Ethics and dissemination The study was approved by the Ethics Committee ‘Comité de Protection des Personnes (CPP) Sud-Méditerranéen III’ on 2 June 2021 and registered with ClinicalTrials.gov (NCT04926142). Findings will be presented in national and international congresses and peer-reviewed journals. Trial registration number NCT04926142.
Open AccessIncidence of atrial fibrillation in cryptogenic stroke with patent foramen ovale closure: protocol for the prospective, observational PFO-AF study
Introduction After closure of patent foramen ovale (PFO) due to stroke, atrial fibrillation (AF) occurs in up to one in five patients. However, data are sparse regarding the possible pre-existence of AF in these patients prior to PFO closure, and about recurrence of AF in the long term after the procedure. No prospective study to date has investigated these topics in patients with implanted cardiac monitor (ICM). The PFO-AF study (registered with ClinicalTrials.gov under the number NCT04926142) will investigate the incidence of AF occurring within 2 months after percutaneous closure of PFO in patients with prior stroke. AF will be identified using systematic ICM. Secondary objectives are to assess incidence and burden of AF in the 2 months prior to, and up to 2 years after PFO closure. Methods and analysis Prospective, multicentre, observational study including 250 patients with an indication for PFO closure after stroke, as decided by interdisciplinary meetings with cardiologists and neurologists. Patients will undergo implantation of a Reveal Linq device (Medtronic). Percutaneous PFO closure will be performed 2 months after device implantation. Follow-up will include consultation, ECG and reading of ICM data at 2, 12 and 24 months after PFO closure. The primary endpoint is occurrence of AF at 2 months, defined as an episode of AF or atrial tachycardia/flutter lasting at least 30 s, and recorded by the ICM and/or any AF or atrial tachycardia/flutter documented on ECG during the first 2 months of follow-up. Ethics and dissemination The study was approved by the Ethics Committee ‘Comité de Protection des Personnes (CPP) Sud-Méditerranéen III’ on 2 June 2021 and registered with ClinicalTrials.gov (NCT04926142). Findings will be presented in national and international congresses and peer-reviewed journals. Trial registration number NCT04926142.
- Open Access
- 16 August 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (16) , 3615
Available Bleeding Scoring Systems Poorly Predict Major Bleeding in the Acute Phase of Pulmonary Embolism
We aimed to compare six available bleeding scores, in a real-life cohort, for prediction of major bleeding in the early phase of pulmonary embolism (PE). We recorded in-hospital characteristics of 2754 PE patients in a prospective observational multicenter cohort contributing 18,028 person-days follow-up. The VTE-BLEED (Venous Thrombo-Embolism Bleed), RIETE (Registro informatizado de la enfermedad tromboembólica en España; Computerized Registry of Patients with Venous Thromboembolism), ORBIT (Outcomes Registry for Better Informed Treatment), HEMORR2HAGES (Hepatic or Renal Disease, Ethanol Abuse, Malignancy, Older Age, Reduced Platelet Count or Function, Re-Bleeding, Hypertension, Anemia, Genetic Factors, Excessive Fall Risk and Stroke), ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation), and HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile International Normalized Ratio, Elderly, Drugs/Alcohol) scores were assessed at baseline. International Society on Thrombosis and Haemostasis (ISTH)-defined bleeding events were independently adjudicated. Accuracy of the overall original 3-level and newly defined optimal 2-level outcome of the scores were evaluated and compared. We observed 82 first early major bleedings (3.0% (95% CI, 2.4–3.7)). The predictive power of bleeding scores was poor (Harrel’s C-index from 0.57 to 0.69). The RIETE score had numerically higher model fit and discrimination capacity but without reaching statistical significance versus the ORBIT, HEMORR2HAGES, and ATRIA scores. The VTE-BLEED and HAS-BLED scores had significantly lower C-index, integrated discrimination improvement, and net reclassification improvement compared to the others. The rate of observed early major bleeding in score-defined low-risk patients was high, between 15% and 34%. Current available scoring systems have insufficient accuracy to predict early major bleeding in patients with acute PE. The development of acute-PE-specific risk scores is needed to optimally target bleeding prevention strategies.
- 16 August 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (16) , 3615
Open AccessAvailable Bleeding Scoring Systems Poorly Predict Major Bleeding in the Acute Phase of Pulmonary Embolism
We aimed to compare six available bleeding scores, in a real-life cohort, for prediction of major bleeding in the early phase of pulmonary embolism (PE). We recorded in-hospital characteristics of 2754 PE patients in a prospective observational multicenter cohort contributing 18,028 person-days follow-up. The VTE-BLEED (Venous Thrombo-Embolism Bleed), RIETE (Registro informatizado de la enfermedad tromboembólica en España; Computerized Registry of Patients with Venous Thromboembolism), ORBIT (Outcomes Registry for Better Informed Treatment), HEMORR2HAGES (Hepatic or Renal Disease, Ethanol Abuse, Malignancy, Older Age, Reduced Platelet Count or Function, Re-Bleeding, Hypertension, Anemia, Genetic Factors, Excessive Fall Risk and Stroke), ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation), and HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile International Normalized Ratio, Elderly, Drugs/Alcohol) scores were assessed at baseline. International Society on Thrombosis and Haemostasis (ISTH)-defined bleeding events were independently adjudicated. Accuracy of the overall original 3-level and newly defined optimal 2-level outcome of the scores were evaluated and compared. We observed 82 first early major bleedings (3.0% (95% CI, 2.4–3.7)). The predictive power of bleeding scores was poor (Harrel’s C-index from 0.57 to 0.69). The RIETE score had numerically higher model fit and discrimination capacity but without reaching statistical significance versus the ORBIT, HEMORR2HAGES, and ATRIA scores. The VTE-BLEED and HAS-BLED scores had significantly lower C-index, integrated discrimination improvement, and net reclassification improvement compared to the others. The rate of observed early major bleeding in score-defined low-risk patients was high, between 15% and 34%. Current available scoring systems have insufficient accuracy to predict early major bleeding in patients with acute PE. The development of acute-PE-specific risk scores is needed to optimally target bleeding prevention strategies.